Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comment on: Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections.

Literature DB >> 22052687

Comment on: Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections.

Theodoros Kelesidis.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2011 PMID： 22052687 PMCID： PMC8445007 DOI： 10.1093/jac/dkr465

Source DB: PubMed Journal: J Antimicrob Chemother ISSN： 0305-7453 Impact factor: 5.758

× No keyword cloud information.

11 in total

1. The role of conjugative transposons in spreading antibiotic resistance between bacteria that inhabit the gastrointestinal tract.

Authors: K P Scott
Journal: Cell Mol Life Sci Date: 2002-12 Impact factor: 9.261

2. Regulation and adaptive evolution of lactose operon expression in Lactobacillus delbrueckii.

Authors: Luciane Lapierre; Beat Mollet; Jacques-Edouard Germond
Journal: J Bacteriol Date: 2002-02 Impact factor: 3.490

3. Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections.

Authors: S Travis King; Justin B Usery; Katherine Holloway; Laura Koeth; Kerry O Cleveland; Michael S Gelfand
Journal: J Antimicrob Chemother Date: 2011-08-16 Impact factor: 5.790

4. What has kept the antibiotic miracle alive?

Authors: Thomas F O'Brien
Journal: N Engl J Med Date: 2011-09-08 Impact factor: 91.245

5. Genetic basis for daptomycin resistance in enterococci.

Authors: Kelli L Palmer; Anu Daniel; Crystal Hardy; Jared Silverman; Michael S Gilmore
Journal: Antimicrob Agents Chemother Date: 2011-04-18 Impact factor: 5.191

6. Genetic basis for in vivo daptomycin resistance in enterococci.

Authors: Cesar A Arias; Diana Panesso; Danielle M McGrath; Xiang Qin; Maria F Mojica; Corwin Miller; Lorena Diaz; Truc T Tran; Sandra Rincon; E Magda Barbu; Jinnethe Reyes; Jung H Roh; Elizabeth Lobos; Erica Sodergren; Renata Pasqualini; Wadih Arap; John P Quinn; Yousif Shamoo; Barbara E Murray; George M Weinstock
Journal: N Engl J Med Date: 2011-09-08 Impact factor: 91.245

7. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients.

Authors: Anita Bhalla; Nicole J Pultz; Amy J Ray; Claudia K Hoyen; Elizabeth C Eckstein; Curtis J Donskey
Journal: Infect Control Hosp Epidemiol Date: 2003-09 Impact factor: 3.254

8. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.

Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerrin L Tyrrell; Helen T Fernandez
Journal: Antimicrob Agents Chemother Date: 2003-01 Impact factor: 5.191

Comment on: Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections.

1. The role of conjugative transposons in spreading antibiotic resistance between bacteria that inhabit the gastrointestinal tract.

2. Regulation and adaptive evolution of lactose operon expression in Lactobacillus delbrueckii.

3. Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections.

4. What has kept the antibiotic miracle alive?

5. Genetic basis for daptomycin resistance in enterococci.

6. Genetic basis for in vivo daptomycin resistance in enterococci.

7. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients.

8. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.

9. Phospholipid biosynthesis in some anaerobic bacteria.

10. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

1. De novo daptomycin-nonsusceptible enterococcal infections.

2. Case-control study comparing de novo and daptomycin-exposed daptomycin-nonsusceptible Enterococcus infections.